<DOC>
	<DOCNO>NCT01971580</DOCNO>
	<brief_summary>Hypothesis : Patients Fontan type palliation limit preload , rate blood return heart passively traverse pulmonary capillary bed . By decrease pulmonary vascular resistance use endothelin receptor antagonist , ventricular filling pressure volume increase simultaneous decrease systemic impedance flow decrease central venous pressure , lead improve capacity increase cardiac output , thereby improvement patient functional status . Patients candidate study randomize double-blind single crossover study . Therapy either ambrisentan placebo continue 12 week , 2 week washout period treatment period . Subjects subject VO2 max test evaluate exercise capacity enrolment , last day treatment period . As component VO2 max test patient 's VE , VCO2 , VE/VCO2 slope , ventilatory anaerobic threshold ( VAT ) , peak work , efficiency , physiologic parameter typically obtain cardiopulmonary testing assess . In addition , patient ask complete SF-36 quality life questionnaire enrollment , last day study period .</brief_summary>
	<brief_title>The Effects Ambrisentan Exercise Capacity Fontan Patients</brief_title>
	<detailed_description />
	<criteria>1 . Patients 18 year age follow Center Adults Congenital Heart Disease Washington University School Medicine Saint Louis Childrens Hospital Fontantype palliation single ventricular physiology . 2 . Patients must within last year treat endothelin receptor antagonist , phosphodiesterase 5 antagonist , prostacyclin analogue . 3 . Female patient must pregnant , study period must use effective contraception ( include barrier method spermicide , intrauterine device , implanon , oral contraceptive ) fertile . 4 . In physicians opinion patient must able complete VO2 max test achieve RER &gt; 1.0 5 . In physicians opinion patient must socially intellectually able adhere treatment regimen followup 6 . Patients must intellectually able reliably complete SF36 questionnaire quality life . 7 . Patients must clinically stable least 3 month prior enrolment . 8 . Patients must surgery within 6 month prior enrolment , plan surgery study period . 9 . Patients must provide informed consent . 1 . Patients 18 year age . 2 . Patients pregnant , nursing , physician 's opinion likely become pregnant . 3 . Patients clinically unstable . 4 . Patients previously treat either endothelin receptor antagonist stop due adverse side effect . 5 . Patients AST ALT &gt; 3 x normal . 6 . Patients know contraindication initiation ambrisentan . 7 . Patients calculate creatinine clearance &lt; 60ml/min 8 . Patients serum hemoglobin concentration &lt; 10mg/dl 9 . Patients poorly control cardiac arrhythmia 10 . Patients unable provide independent informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>